Role of innate immune system in systemic sclerosis

Seminars in Immunopathology

Volumn 37, Issue 5, 2015, Pages 511-517

  Fullard, Nicola ^a   O’Reilly, Steven ^a  

^a DURHAM UNIVERSITY   (United Kingdom)

Author keywords

Inflammasomes; Innate immunity; NODs; Systemic sclerosis; TLRs

Indexed keywords

AMYLOID A PROTEIN; ECTODYSPLASIN A; FIBRONECTIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLAMMASOME; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 4; INTERLEUKIN 6; SINGLE STRANDED RNA; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 8; AUTOANTIBODY; PATTERN RECOGNITION RECEPTOR; TOLL LIKE RECEPTOR;

ANTIGEN BINDING; CYTOKINE RELEASE; FIBROSING ALVEOLITIS; HEART GRAFT; HUMAN; INNATE IMMUNITY; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SYSTEMIC SCLEROSIS; UPREGULATION; IMMUNOLOGY; METABOLISM;

AUTOANTIBODIES; HUMANS; IMMUNITY, INNATE; RECEPTORS, PATTERN RECOGNITION; SCLERODERMA, SYSTEMIC; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS;

EID: 84940829591     PISSN: 18632297     EISSN: 18632300     Source Type: Journal    
DOI: 10.1007/s00281-015-0503-7     Document Type: Review

References (60)

1. Kawai T, Akira S (2011) Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 34(5):637–650
2. Loo Y-M, Gale M Jr (2011) Immune signaling by RIG-I-like receptors. Immunity 34(5):680–692
3. Ciechomska M, Cant R, Finnigan J, van Laar JM, O’Reilly S (2013) Role of Toll-like receptors in systemic sclerosis. Expert Reviews in Molecular Medicine, 2013. 15: p. null-null
4. Medzhitov R, Preston-Hurlburt P, Janeway CA (1997) A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 388(6640):394–397
5. Carty M, Goodbody R, Scheoder M, Stack J, Moynagh, PN, Bowie AG (2006) The human adaptor SARM negatively regulates adaptor protein TRIF-dependent Toll-like receptor signaling. Nat Immunol 7(10):1074–1081
6. Kim Y, Zhou P, Qian L, Chaung JZ, Lee J, Li C, Iadecola C, Nathan C, Ding A (2007) MyD88-5 links mitochondria, microtubules, and JNK3 in neurons and regulates neuronal survival. J Exp Med 204(9):2063–2074
7. Kawai T, Akira S (2010) The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 11(5):373–384
8. Liu G, Friggeri A, Yang Y, Park YJ, Tsuruta Y, Abraham E (2009) miR-147, a microRNA that is induced upon Toll-like receptor stimulation, regulates murine macrophage inflammatory responses. Proc Natl Acad Sci 106(37):15819–15824
9. Taganov KD, Boldin MP, Chang KJ, Baltimore D (2006) NF-κB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci 103(33):12481–12486
10. Matzinger P (1994) Tolerance, danger, and the extended family. Annu Rev Immunol 12(1):991–1045
11. Tannahill GM, Curtis AM, Adamik J, Palsson-McDermott EM, Mcketrick AF, Goel G, Frezza C, Bernard NJ, Kelly B, Foley NH, Zheng, L, Gardet A, Tong Z, JAny SS, Corr SC, Haneklaus M, Caffrey BE, Pierce K, Walmsley S, Beasley FC, Cummins E, Nizet V, Whyte M, Taylor CT, Lin H, Masters SL, Gottlieb E, Kelly VP, Clish C, Auron PE et al (2013) Succinate is an inflammatory signal that induces IL-1[bgr] through HIF-1[agr]. Nature 496(7444):238–242
12. Cheng N et al (2008) Cutting edge: TLR2 is a functional receptor for acute-phase serum amyloid A. J Immunol 181(1):22–26
13. Björkman L et al (2008) Serum amyloid A mediates human neutrophil production of reactive oxygen species through a receptor independent of formyl peptide receptor like-1. J Leukoc Biol 83(2):245–253
14. Agarwal S et al (2011) Toll-like receptor 3 upregulation by type I interferon in healthy and scleroderma dermal fibroblasts. Arthritis Res Ther 13(1):R3
15. O’Reilly S et al (2014) Serum amyloid a induces interleukin-6 in dermal fibroblasts via toll-like receptor 2, interleukin-1 receptor-associated kinase 4 and nuclear factor-κB. Immunology 143(3):331–340
16. O’Reilly S et al (2012) Interleukin-6, its role in fibrosing conditions. Cytokine Growth Factor Rev 23(3):99–107
17. Lakota K et al (2015) Serum amyloid A is a marker for pulmonary involvement in systemic sclerosis. PLoS One 10(1), e0110820
18. Broen JCA et al (2012) A rare polymorphism in the gene for toll-like receptor 2 is associated with systemic sclerosis phenotype and increases the production of inflammatory mediators. Arthritis Rheum 64(1):264–271
19. Koumakis E et al (2012) Brief report: candidate gene study in systemic sclerosis identifies a rare and functional variant of the TNFAIP3 locus as a risk factor for polyautoimmunity. Arthritis Rheum 64(8):2746–2752
20. Poltorak A et al (1998) Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282(5396):2085–2088
21. Chen GY, Nuñez G (2010) Sterile inflammation: sensing and reacting to damage. Nat Rev Immunol 10(12):826–837
22. Lotze MT, Tracey KJ (2005) High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 5(4):331–342
23. Park JS et al (2004) Involvement of Toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem 279(9):7370–7377
24. Jiang D et al (2005) Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nat Med 11(11):1173–1179
25. Midwood K et al (2009) Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease. Nat Med 15(7):774–780
26. Okamura Y et al (2001) The extra domain a of fibronectin activates Toll-like receptor 4. J Biol Chem 276(13):10229–10233
27. Bhattacharyya S et al (2014) FibronectinEDA promotes chronic cutaneous fibrosis through Toll-like receptor signaling. Science Translational Medicine 232:232ra50
28. Muro AF et al (2008) An essential role for fibronectin extra type III domain a in pulmonary fibrosis. Am J Respir Crit Care Med 177(6):638–645
29. Booth AJ et al (2012) Recipient-derived EDA fibronectin promotes cardiac allograft fibrosis. J Pathol 226(4):609–618
30. Bhattacharyya S et al (2013) Toll-like receptor 4 signaling augments transforming growth factor-β responses: a novel mechanism for maintaining and amplifying fibrosis in scleroderma. Am J of Pathol 182(1):192–205
31. Takahashi T et al (2015) Amelioration of tissue fibrosis by Toll-like receptor 4 knockout in murine models of systemic sclerosis. Arthritis Rheum 67(1):254–265
32. Hügle T et al (2013) Tumor necrosis factor–costimulated T lymphocytes from patients with systemic sclerosis trigger collagen production in fibroblasts. Arthritis Rheum 65(2):481–491
33. Ma J et al (2014) TLR4 activation promotes podocyte injury and interstitial fibrosis in diabetic nephropathy. PLoS One 9(5), e97985
34. van Bon L et al (2014) Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. N Engl J Med 370(5):433–443
35. van Bon L et al (2014) Proteomic analysis of plasma identifies the Toll-like receptor agonists S100A8/A9 as a novel possible marker for systemic sclerosis phenotype. Ann Rheum Dis 73(8):1585–1589
36. Heil F et al (2004) Species-specific recognition of single-stranded RNA via Toll-like receptor 7 and 8. Science 303(5663):1526–1529
37. Farina GA et al (2010) Poly(I:C) drives type I IFN- and TGF[beta]-mediated inflammation and dermal fibrosis simulating altered gene expression in systemic sclerosis. J Invest Dermatol 130(11):2583–2593
38. Ciechomska M et al (2013) Toll-like receptor-mediated, enhanced production of profibrotic TIMP-1 in monocytes from patients with systemic sclerosis: role of serum factors. Ann Rheum Dis 72(8):1382–1389
39. Vollmer J et al (2005) Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8. J Exp Med 202(11):1575–1585
40. Carmona FD et al (2013) The systemic lupus erythematosus IRF5 risk haplotype is associated with systemic sclerosis. PLoS One 8(1), e54419
41. Kim D et al (2008) Induction of interferon-α by scleroderma sera containing autoantibodies to topoisomerase I: association of higher interferon-α activity with lung fibrosis. Arthritis Rheum 58(7):2163–2173
42. Wermuth PJ, Jimenez SA (2012) Gadolinium compounds signaling through TLR 4 and TLR 7 in normal human macrophages: establishment of a proinflammatory phenotype and implications for the pathogenesis of nephrogenic systemic fibrosis. J Immunol 189(1):318–327
43. Yanai H et al (2009) HMGB proteins function as universal sentinels for nucleic-acid-mediated innate immune responses. Nature 462(7269):99–103
44. Farina A et al (2014) Epstein-Barr virus infection induces aberrant TLR activation pathway and fibroblast-myofibroblast conversion in scleroderma. J Invest Dermatol 134(4):954–964
45. Lok SS et al (2001) Epstein–Barr virus and wild p53 in idiopathic pulmonary fibrosis. Respir Med 95(10):787–791
46. Dieudé P et al (2011) NLRP1 influences the systemic sclerosis phenotype: a new clue for the contribution of innate immunity in systemic sclerosis-related fibrosing alveolitis pathogenesis. Ann Rheum Dis 70(4):668–674
47. Artlett CM et al (2011) The inflammasome activating caspase 1 mediates fibrosis and myofibroblast differentiation in systemic sclerosis. Arthritis Rheum 63(11):3563–3574
48. Wree A et al (2014) NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation, and fibrosis in mice. Hepatology 59(3):898–910
49. Bracey NA et al (2014) Mitochondrial NLRP3 protein induces reactive oxygen species to promote smad protein signaling and fibrosis independent from the inflammasome. J Biol Chem 289(28):19571–19584
50. Wang W et al (2013) Inflammasome-independent NLRP3 augments TGF-β signaling in kidney epithelium. J Immunol 190(3):1239–1249
51. Duewell P et al (2010) NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 464(7293):1357–1361
52. Huang H et al (2013) Histones activate the NLRP3 inflammasome in Kupffer cells during sterile inflammatory liver injury. J Immunol 191(5):2665–2679
53. Hornung V et al (2008) Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol 9(8):847–856
54. Arslan F et al (2012) Treatment with OPN-305, a humanized anti–Toll-like receptor-2 antibody, reduces myocardial ischemia/reperfusion injury in pigs. Circ Cardiovasc Inter 5(2):279–287
55. Hamidi S, Schäfer-Korting M, Weindl G (2014) TLR2/1 and sphingosine 1-phosphate modulate inflammation, myofibroblast differentiation and cell migration in fibroblasts. Biochim Biophysic Acta (BBA) 1841(4):484–494
56. Opal SM et al (2013) Effect of eritoran, an antagonist of md2-tlr4, on mortality in patients with severe sepsis: the access randomized trial. JAMA 309(11):1154–1162
57. Sacre SM et al (2007) The Toll-like receptor adaptor proteins MyD88 and Mal/TIRAP contribute to the inflammatory and destructive processes in a human model of rheumatoid arthritis. Am J Pathology 170(2):518–525
58. Coll RC et al. (2015) A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat Med. advance online publication
59. Lamkanfi M et al (2009) Glyburide inhibits the cryopyrin/Nalp3 inflammasome. J Cell Biol 187(1):61–70
60. Roelofs MF et al (2008) The functional variant (Asp299gly) of toll-like receptor 4 (TLR4) influences TLR4-mediated cytokine production in rheumatoid arthritis. J of Rheum 35(4):558–561